Premium
P3‐034: CONTINUOUS COMMUNITY ENGAGEMENT IMPROVES RECRUITMENT OF OLDER AFRICAN AMERICANS FOR GENETIC STUDIES IN ALZHEIMER'S DISEASE
Author(s) -
Byfield Grace,
Starks Takiyah,
Cuccaro Michael L.,
Adams Larry D.,
Whitehead Patrice L.,
Hamilton-Nelson Kara L.,
Reitz Christiane,
Beecham Gary W.,
Reyes-Dumeyer Dolly,
Haines Jonathan L.,
Mayeux Richard,
Vance Jeffery M.,
Pericak-Vance Margaret AA.,
Edwards Christopher,
Byrd Goldie S.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1389
Subject(s) - outreach , gerontology , disease , community based participatory research , participatory action research , medicine , citizen journalism , psychology , sociology , political science , pathology , anthropology , law
baseline MMSE variability and the association of pre-intervention MMSE variability with ADAS-Cog change at 52 weeks in the entire trial cohort, collapsed across treatment assignment. Results:Change on the MMSE from screening to baseline was assessed in 373 participants. On average, participants were 71.9 (SD1⁄47.9) years old; had completed 15.1 (SD1⁄43.0) years of education; and scored 18.1 (SD1⁄43.0) on the MMSE at screening. Average change on the MMSE from screening to baseline was -0.21 (SD1⁄42.60) points. Change scores were normally distributed around the mean, as shown in Figure 1; however, there were outliers, with some participant’s scores changing as much as 10-12 points. To evaluate whether pre-randomization cognitive variability was associated with study outcome, participants were divided into quartiles based on their screening-to-baseline MMSE change score. Quartiles of pre-randomization variability did not differ in change on the ADAS-Cog at 52 weeks (Figure 2; F(3,338)1⁄41.49; p1⁄40.22). Conclusions:In this trial cohort of mildto-moderate AD participants, variability in MMSE score from screening to baseline was normally distributed around a small mean change of -0.21 points. Pre-randomization variability was not associated with ADAS-Cog change at 52 weeks. These results suggest that potential trial participants need not be excluded from participation based upon pre-randomization variability on mental-status screening.